학술논문

Tackling the Challenges of Product Development Through a Collaborative Rare Disease Network: The Foundation Fighting Blindness Consortium
Document Type
article
Source
Translational Vision Science & Technology. 10(4)
Subject
Eye Disease and Disorders of Vision
Orphan Drug
Pediatric
Neurosciences
Rare Diseases
Neurodegenerative
Genetics
Eye
Blindness
Choroideremia
Color Vision Defects
Humans
Leber Congenital Amaurosis
inherited retinal degenerations
retinitis pigmentosa
consortium
infrastructure
genetic
natural history
outcome measures
Foundation Fighting Blindness Consortium Investigator Group
Biomedical Engineering
Opthalmology and Optometry
Language
Abstract
The Foundation Fighting Blindness, a 501(c)(3) nonprofit organization, established an international consortium of inherited retinal disease specialists in 2016, with a mission to accelerate the development of treatments for rare, inherited retinal degenerations, such as retinitis pigmentosa, Stargardt disease, Leber congenital amaurosis, Usher syndrome, choroideremia, and achromatopsia. The Consortium accomplishes its mission by evaluating novel outcome measures, sharing standardized study protocols and datasets, and disseminating findings. Having established research infrastructure in the first 3 years, including 39 global research sites, the network is now poised to expand its infrastructure for trials of new therapies in partnership with industry. This model represents an innovative approach to overcome challenges of therapeutic development for rare diseases.